Boulder, CO
OnKure is committed to the discovery and development of best-in-class precision medicines that target biologically validated drivers of cancer.
onkuretherapeutics.comThese are collections OnKure is a part of. Click on the collection name to view similar companies.
Post Ipo Equity
$65,000,000
Series C
$54,000,000
Post Ipo Equity
$55,000,000
Post Ipo Secondary
$20,000,000
Series B
$56,649,181
IPO
Unknown
Series B
$95,000,000
Debt Financing
$2,000,000
Series A
$50,000,000
Series A
$7,000,000
Seed
$495,000
Seed
$599,705
Grant
$250,000
Pre Seed
$499,985
0 out of 5 stars
Based on 0 reviews
Worked here? Share your experience. Help others decide if this company is right for them. Write a review on OnKure.